School personnel information

写真b

FUJITA Jiro


Keyword

Leukemia,Lymphoma,Adult T-cell leukemia/lymphoma

Organization 【 display / non-display

  • 2012.04.01 - 2014.03.31, Division of Medicine, Graduate School of Medicine, Assistant Professor

  • 2014.04.01 - , Division of Medicine, Graduate School of Medicine, Assistant Professor

Education 【 display / non-display

Osaka University Faculty of Medicine  Graduated 1999.03
Osaka University Graduate School, Division of Medical Sciences  Completed 2011.03
 

Academic Papers 【 display / non-display

  • Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation., Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y., International Journal of Hematology,109(2):197-205, 2019.02, Papers

  • A Novel Unifrac-Based Analytical Method for Determining Sequential Changes in Gut Microbiota after Hematopoietic Stem Cell Transplantation., Shinsuke Kusakabe, Kentaro Fukushima, Tetsuo Maeda, Takafumi Yokota, Ritsuko Nakai, Akihisa Hino, Yasuhiro Nagate, Jiro Fujita, Motooka Daisuke, Shota Nakamura, Hirohiko Shibayama, Yuzuru Kanakura, The American Society of Hematology 60th Annual Meeting,1, 2018.12, Other

  • Ectonucleosidase CD39 Is Highly Expressed on ATLL Cells and Suppresses the Immune Response through theAdenosine Pathway., Yasuhiro Nagate, Sachiko Ezoe, Jiro Fujita, Takafumi Yokota, Michiko Ichii, Akira Tanimura, Yukiko Doi, Tomoaki Ueda, Jun Toda, Hirohiko Shibayama, Kenji Oritani, Yuzuru Kanakura, The American Society of Hematology 60th Annual Meeting,1, 2018.12, Other

  • Addition of melphalan to fludarabine / busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone marrow transplantation/peripheral blood stem cell transplantation., Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y, The American Society of Hematology 60th Annual Meeting,1, 2018.12, Other

  • Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation, Tomoaki Ueda,Tetsuo Maeda,Shinsuke Kusakabe,Jiro Fujita,Kentaro Fukushima,Takafumi Yokota,Hirohiko Shibayama,Yoshiaki Tomiyama,Yuzuru Kanakura, Internal Journal of Hematology, 2018.11, Papers

display all >>